About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is a company founded in 2010 by Geoffrey Dow.. 60 Degrees Pharmaceuticals has raised $1.76 million across 2 funding rounds. The company has 3 employees as of December 31, 2024. 60 Degrees Pharmaceuticals offers products and services including Malaria Medicine, Dengue Fever Treatment, Babesiosis Medicine, and Fungal Diseases Product. 60 Degrees Pharmaceuticals operates in a competitive market with competitors including Jaguar Health, Vyera Pharmaceuticals, ACE Pharmaceuticals, Artemis Therapeutics and Travelan, among others.
- Employees 3 as on 31 Dec, 2024
- Founders Geoffrey Dow
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name 60 Degrees Pharmaceuticals, Inc
-
Annual Revenue
$681.35 K168.7as on Dec 31, 2024
-
Net Profit
$-7.95 M-114.57as on Dec 31, 2024
-
EBITDA
$-9.65 M-90.95as on Dec 31, 2024
-
Total Equity Funding
$1.76 M (USD)
in 2 rounds
-
Latest Funding Round
-
Investors
-
Employee Count
3
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SXTP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals offers a comprehensive portfolio of products and services, including Malaria Medicine, Dengue Fever Treatment, Babesiosis Medicine, and Fungal Diseases Product. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Prevents and treats malaria through innovative lifecycle disruption.
Addresses dengue infections to meet global medical needs.
Develops treatments for babesiosis and related parasitic diseases.
Targets fungal infections via research-based therapies.
Funding Insights of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals has successfully raised a total of $1.76M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(24 May 2023)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Seed - 60 Degrees Pharmaceuticals | Valuation |
investors |
|
| May, 2023 | Amount | Debt – Conventional - 60 Degrees Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by 60 Degrees Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - 60 Degrees Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
60 Degrees Pharmaceuticals Comparisons
Competitors of 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jaguar Health, Vyera Pharmaceuticals, ACE Pharmaceuticals, Artemis Therapeutics and Travelan, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel gastrointestinal products for humans and animals are developed sustainably.
|
|
| domain | founded_year | HQ Location |
Delivers comprehensive small molecule therapeutics for toxoplasmosis and neglected parasitic infections.
|
|
| domain | founded_year | HQ Location |
Drugs are manufactured for sister companies in the Netherlands.
|
|
| domain | founded_year | HQ Location |
Cameo provides tools for strain design in metabolic engineering projects.
|
|
| domain | founded_year | HQ Location |
Develops and commercializes antibodies for preventing gastrointestinal infections during travel.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on 60 Degrees Pharmaceuticals
Frequently Asked Questions about 60 Degrees Pharmaceuticals
When was 60 Degrees Pharmaceuticals founded?
60 Degrees Pharmaceuticals was founded in 2010 and raised its 1st funding round 13 years after it was founded.
Who is the current CEO of 60 Degrees Pharmaceuticals?
Geoffrey Dow is the current CEO of 60 Degrees Pharmaceuticals. They have also founded this company.
Is 60 Degrees Pharmaceuticals a funded company?
60 Degrees Pharmaceuticals is a funded company, having raised a total of $1.76M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.76M, raised on May 24, 2023.
How many employees does 60 Degrees Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at 60 Degrees Pharmaceuticals is 3.
What is the annual revenue of 60 Degrees Pharmaceuticals?
Annual revenue of 60 Degrees Pharmaceuticals is $681.35K as on Dec 31, 2024.
What does 60 Degrees Pharmaceuticals do?
Founded in 2010, 60 Degrees Pharmaceuticals operates in the biopharmaceutical sector, focusing on the discovery and development of treatments for tropical diseases such as dengue and malaria. The pipeline includes 60P001, an alpha-glucosidase inhibitor, and 60P002, a platelet activating factor receptor antagonist, both in Phase 1b for dengue fever. Preparations are underway for the 2018 commercial launch of 60P003 for malaria prevention, following a U.S. Army agreement.
Who are the top competitors of 60 Degrees Pharmaceuticals?
60 Degrees Pharmaceuticals's top competitors include Jaguar Health, ACE Pharmaceuticals and MalarVx.
What products or services does 60 Degrees Pharmaceuticals offer?
60 Degrees Pharmaceuticals offers Malaria Medicine, Dengue Fever Treatment, Babesiosis Medicine, and Fungal Diseases Product.
Is 60 Degrees Pharmaceuticals publicly traded?
Yes, 60 Degrees Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol SXTP.
What is 60 Degrees Pharmaceuticals's ticker symbol?
The ticker symbol of 60 Degrees Pharmaceuticals is SXTP on NASDAQ.